Mineralys

Mineralys Therapeutics

The company develops an aldosterone synthase inhibitor medicine to treat patients with uncontrolled or treatment-resistant hypertension and chronic kidney disease.

CINC

This company develops biopharmaceutical treatments for cardio-renal diseases, primarily for patients with hypertension and chronic kidney disease.

Pathalys Pharma

This biopharmaceutical company develops treatments for secondary hyperparathyroidism in patients with end-stage kidney disease undergoing dialysis.

Ardian

This company develops medical devices for catheter-based renal denervation to treat hypertension in patients with high blood pressure.

River Renal

This clinical-stage biotechnology company develops novel pharmaceutical therapies targeting orphan renal diseases for patients with unmet medical needs.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.

MediTrak Life

This company develops continuous physiological monitoring technology and digital solutions for clinicians to manage chronic conditions such as hypertension.

Cerenis Therapeutics Holding SA

This biopharmaceutical company develops high-density lipoprotein therapies to treat patients with cardiovascular and metabolic diseases, as well as renal and oncology conditions.